睿知中国医院研究地图
候选清单

正在招募乳腺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  2. 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06830889,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:仅女性

    登记记录的入选字段

  2. Patients with histologically confirmed HER2-positive invasive breast cancer;

    入选标准第 4 条

    The presence of residual invasive cancer confirmed by postoperative pathological examination must meet one of the conditions specified in the protocol;

    入选标准第 6 条

  3. Before neoadjuvant therapy, the clinical TNM staging was T1-4, N0-3, M0 (excluding T1N0) based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system;

    入选标准第 5 条

  4. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

    入选标准第 12 条

    Received previous HER2-ADC, immunotherapy, or other antitumor biological therapy;

    排除标准第 6 条

    Prior treatment with anthracyclines, doxorubicin equivalent cumulative dose > 240 mg/m2; Cumulative dose of epirubicin or liposomal doxorubicin hydrochloride > 480 mg/m2;

    排除标准第 8 条

  5. ECOG score 0 or 1;

    入选标准第 11 条

  6. Other primary malignancies diagnosed within 5 years before the first dose;

    排除标准第 5 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06830889,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Sign the informed consent form voluntarily and follow the protocol requirements;
  2. Women aged ≥18 years and ≤75 years at the time of written informed consent;
  3. Expected survival time ≥6 months;
  4. Patients with histologically confirmed HER2-positive invasive breast cancer;
  5. Before neoadjuvant therapy, the clinical TNM staging was T1-4, N0-3, M0 (excluding T1N0) based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system;
  6. The presence of residual invasive cancer confirmed by postoperative pathological examination must meet one of the conditions specified in the protocol;
  7. Previous neoadjuvant therapy should meet the prescribed treatment conditions;
  8. Had received radical mastectomy;
  9. Determine hormone receptor (HR) status;
  10. The interval between radical surgery and randomization was at least 3 weeks and at most 12 weeks;
  11. ECOG score 0 or 1;
  12. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
  13. No blood transfusion within 14 days before the first use of the study drug and no use of colony-stimulating factors were allowed;
  14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients should use adequate and highly effective contraception during the entire treatment cycle and for 7 months after the end of treatment.

排除标准:Exclusion Criteria:

  1. A diagnosis of stage IV metastatic breast cancer was made;
  2. Bilateral breast cancer;
  3. Any previous history of breast cancer (unilateral or contralateral) except for lobular carcinoma in situ (LCIS);
  4. Evidence of clinically significant residual disease or recurrent or metastatic disease after neoadjuvant therapy and surgery;
  5. Other primary malignancies diagnosed within 5 years before the first dose;
  6. Received previous HER2-ADC, immunotherapy, or other antitumor biological therapy;
  7. Subjects are participating in other clinical studies and receiving anti-tumor treatment;
  8. Prior treatment with anthracyclines, doxorubicin equivalent cumulative dose > 240 mg/m2; Cumulative dose of epirubicin or liposomal doxorubicin hydrochloride > 480 mg/m2;
  9. History of severe cardiovascular or cerebrovascular disease within six months before screening;
  10. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
  11. Poorly controlled hypertension (systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 100 mmHg);
  12. Complicated with pulmonary diseases leading to severe impairment of lung function;
  13. A history of ILD/interstitial pneumonia requiring steroid therapy, current ILD/interstitial pneumonia, or suspected such disease during screening; CTCAE v5.0 was used to define grade ≥3 pulmonary disease and grade ≥2 radiation pneumonitis;
  14. Human immunodeficiency virus antibody (HIVAb) positive, active hepatitis B virus infection, liver cirrhosis, or hepatitis C virus infection;
  15. Had a serious infection within 4 weeks before the first dose of study drug; There was active pulmonary inflammation at the time of screening;
  16. Were receiving \&gt within 2 weeks before the first dose; 10mg/d prednisone systemic corticosteroids or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy;
  17. Patients with a history of severe allergy to recombinant humanized antibodies or to any of the excipents of BL-M07D1;
  18. Known hypersensitivity or delayed hypersensitivity to certain components of T-DM1 or similar drugs, or known contraindications to T-DM1;
  19. Had a history of autologous or allogeneic stem cell transplantation or organ transplantation;
  20. Have a severe neurological or psychiatric illness;
  21. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
  22. Intestinal obstruction, Crohn's disease, ulcerative colitis or chronic diarrhea;
  23. Subjects scheduled to receive live vaccine or within 28 days before the first dose;
  24. Patients with other serious physical and laboratory abnormalities or poor adherence that may increase the risk of participating in the study, or interfere with the results of the study, and patients who were deemed by the investigators to be unsuitable for participation in the study.

引自 ClinicalTrials.gov, NCT06830889, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06830889,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06830889